25th World Congress of Dermatology (WCD Singapore 2023)

In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).

Platelet-rich fibrin matrix (PRFM) compares favourably with platelet-rich plasma (PRP) in the treatment of chronic trophic ulcer associated with leprosy, as shown in the results of an observer-blind, noninferiority randomized controlled trial.

Treatment with a microencapsulated benzoyl peroxide (E-BPO) 5% cream contributes to changes in the microbiome of the skin and results in improvements in moderate to severe rosacea, according to a study presented at the recent WCD 2023.

A single injection of intralesional botulinum toxin (BTX) demonstrates long-term efficacy and is well tolerated in patients with nail psoriasis, according to a randomized intraindividual controlled study presented at the recent WCD 2023. BTX is also as effective as multiple intralesional steroid injections.

The anti-interleukin (IL)-36 receptor monoclonal antibody spesolimab not only helps treat generalized pustular psoriasis (GPP) flares but also prevent them, according to the results of the Effisayil 2 study presented at WCD 2023.